Metagenomi (NASDAQ:MGX) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.55) by 10.91 percent. This is a 10.29 percent increase over losses of $(0.68) per share from the same period last year. The company reported quarterly sales of $1.248 million which missed the analyst consensus estimate of $5.925 million by 78.94 percent. This is a 69.76 percent decrease over sales of $4.127 million the same period last year.